Stuart Sprague to Renal Insufficiency, Chronic
This is a "connection" page, showing publications Stuart Sprague has written about Renal Insufficiency, Chronic.
Connection Strength
7.746
-
An update on investigation and management of renal bone disease. Curr Opin Endocrinol Diabetes Obes. 2025 Aug 01; 32(4):135-141.
Score: 0.695
-
Small Intestinal Phosphate Absorption: Novel Therapeutic Implications. Am J Nephrol. 2021; 52(7):522-530.
Score: 0.541
-
Secondary Hyperparathyroidism in a Patient with CKD. Clin J Am Soc Nephrol. 2020 07 01; 15(7):1041-1043.
Score: 0.497
-
Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease. Am J Nephrol. 2019; 49(2):114-124.
Score: 0.453
-
Should phosphate management be limited to the KDIGO/ KDOQI guidelines? Semin Dial. 2018 07; 31(4):377-381.
Score: 0.430
-
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325.
Score: 0.386
-
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12.
Score: 0.381
-
Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016 Apr; 67(4):559-66.
Score: 0.357
-
Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014; 40(6):535-45.
Score: 0.342
-
Women and CKD-mineral and bone disorder. Adv Chronic Kidney Dis. 2013 Sep; 20(5):423-6.
Score: 0.312
-
Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013 Feb; 8(2):321.
Score: 0.295
-
CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis. 2013 Feb; 61(2):310-25.
Score: 0.294
-
The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol. 2013 Feb; 8(2):313-8.
Score: 0.293
-
Impact of CKD on coronary artery calcifications. Am J Kidney Dis. 2011 Oct; 58(4):503-5.
Score: 0.273
-
Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008 Jan-Feb; 14(1):18-27.
Score: 0.210
-
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
Score: 0.173
-
Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with CKD. Kidney360. 2024 05 01; 5(5):681-689.
Score: 0.162
-
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial. J Am Soc Nephrol. 2024 01 01; 35(1):57-65.
Score: 0.159
-
Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360. 2022 02 24; 3(2):258-268.
Score: 0.138
-
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec; 20(12):1463-1472.
Score: 0.137
-
Medullary Blood Oxygen Level-Dependent MRI Index (R2*) is Associated with Annual Loss of Kidney Function in Moderate CKD. Am J Nephrol. 2020; 51(12):966-974.
Score: 0.130
-
Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clin J Am Soc Nephrol. 2020 06 08; 15(6):776-783.
Score: 0.124
-
A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. J Am Soc Nephrol. 2020 01; 31(1):161-174.
Score: 0.121
-
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial. J Am Soc Nephrol. 2019 06; 30(6):1096-1108.
Score: 0.116
-
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293.
Score: 0.114
-
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. J Diabetes Complications. 2018 Dec; 32(12):1113-1117.
Score: 0.110
-
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148.
Score: 0.109
-
Renal Blood Oxygenation Level-Dependent Magnetic Resonance Imaging: A Sensitive and Objective Analysis. Invest Radiol. 2015 Dec; 50(12):821-7.
Score: 0.091
-
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. J Am Soc Nephrol. 2015 Oct; 26(10):2328-39.
Score: 0.088
-
Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016 Feb; 29(1):63-70.
Score: 0.086
-
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010 May; 55(5):773-99.
Score: 0.061
-
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
Score: 0.031
-
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014 Sep; 86(3):638-47.
Score: 0.020
-
Impact of serum source and inflammatory cytokines on the isolation of endothelial colony-forming cells from peripheral blood. J Tissue Eng Regen Med. 2014 Sep; 8(9):747-56.
Score: 0.018